EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

The urinary albumin‐to‐creatinine ratio can direct personalized prevention and treatment for cardiovascular and chronic kidney disease

Holly J Kramer iD, George L Bakris iD

Journal of Internal Medicine · 2026

DOI: 10.1111/joim.70066 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Internal Medicine, 2026. Verfasst von Holly J Kramer und 1 weiteren Autor:innen. Beteiligte Einrichtung: Departments of Public Health Sciences and Medicine, Division of Nephrology and Hypertension, Loyola University Chicago, Maywood, Illinois, USA. Hauptthemen laut MEDLINE: Renal Insufficiency, Chronic, Cardiovascular Diseases, Albuminuria, Creatinine. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 149 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Increased urinary albumin excretion is a strong predictor for cardiovascular events in persons with and without decreased glomerular filtration rate and can be assessed with the urinary albumin‐to‐creatinine ratio (UACR), which is a selective, sensitive, and convenient method for patients. As UACR levels ≥30 mg/g indicate heightened risk for cardiovascular disease (CVD) and chronic kidney disease (CKD) progression, this biomarker may be used to personalize preventive care. Among individuals with UACR ≥30 mg/g, reducing the UACR by at least 30% from the pretreatment (baseline) value is associated with a reduction in the risk for both cardiovascular and kidney events. Monitoring change in the UACR after drug treatment starts can be used to determine a need for medication adjustments, such as dose escalations, switching drug class, or adding further drug classes in patients with UACR ≥30 mg/g. In this review, we discuss how the biomarker UACR may be used to determine CVD and CKD risk, guide treatment, and monitor treatment response, and that the UACR is an effective tool to personalize medicine in patients with CKD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Renal Insufficiency, ChronicCardiovascular DiseasesAlbuminuriaCreatininePrecision MedicineHumansBiomarkersGlomerular Filtration Rate

Stichwörter der Autor:innen

albumin‐to‐creatinine ratiocardiovascular diseasechronic kidney diseasehypertensionpreventiontype 2 diabetes mellitus

Substanzen

BiomarkersCreatinine

Autor:innen und Institutionen

  • Departments of Public Health Sciences and Medicine, Division of Nephrology and Hypertension, Loyola University Chicago, Maywood, Illinois, USA.
  • Department of Medicine, Division of Nephrology, University of Chicago Medicine, Chicago, Illinois, USA.

ORCID-Profile: Holly J Kramer, George L Bakris

Zitieren

APA

Kramer, H. J., & Bakris, G. L. (2026). The urinary albumin‐to‐creatinine ratio can direct personalized prevention and treatment for cardiovascular and chronic kidney disease. Journal of Internal Medicine. https://doi.org/10.1111/joim.70066

Vancouver

Kramer HJ, Bakris GL. The urinary albumin‐to‐creatinine ratio can direct personalized prevention and treatment for cardiovascular and chronic kidney disease. Journal of Internal Medicine. 2026. doi:10.1111/joim.70066

BibTeX
@article{Kramer2026,
  author = {Kramer, Holly J and Bakris, George L},
  title = {The urinary albumin‐to‐creatinine ratio can direct personalized prevention and treatment for cardiovascular and chronic kidney disease},
  journal = {Journal of Internal Medicine},
  year = {2026},
  doi = {10.1111/joim.70066}
}
Kostenlos starten →